Pol Escudé Martinez de Castilla

Pol Escudé Martinez de Castilla

Auto-generated profile, based on publicly available information

Pol Escudé Martinez de Castilla

Central Diagnostic Laboratory Research, University Medical Center Utrecht

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PCPol Escudé Martinez de Castilla
Pol Escudé Martinez de Castilla
Vincenzo VerdiVincenzo Verdi
Vincenzo Verdi
WVWillemijn de Voogt
Willemijn de Voogt
MSMariona Estapé Sentí
Mariona Estapé Sentí
AKArnold C. Koekman
Arnold C. Koekman
RSRaymond Schiffelers
Raymond Schiffelers
Prostate cancer (PCa) ranks as the fifth leading cause of cancer‐related deaths among men worldwide. In 10–20% of the cases, PCa progresses to an incurable, castration‐resistant stage. Castration‐resistant PCa cells often overexpress prostate‐specific membrane antigen (PSMA), a membrane protein that may serve as their Achilles' heel. Over the past decades, RNA‐based therapeutics have emerged as promising treatments for a vast array of diseases, including cancer. In this study, with the ultimate goal of developing a targeted therapy for PCa, lipid nanoparticles (LNPs) are decorated with an anti‐PSMA nanobody using click chemistry with a PEG‐lipid. Direct stochastic optical reconstruction microscopy (dSTORM) and cluster analysis confirm the presence of at least one nanobody on the surface of 80% of LNPs. These anti‐PSMA LNPs exhibit enhanced and specific uptake, and mRNA transfection in PSMA+ cancer cells both in vitro and in a Zebrafish (ZF) metastatic PCa xenograft model. Additionally, in a mouse PSMA‐positive xenograft model, systemic administration results in increased LNP accumulation, but not functional mRNA delivery. These findings underscore both the potential and the challenges of using a PSMA‐targeted lipid nanoparticle system for mRNA delivery into advanced prostate cancer tumors.

18 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LWLaura Wormser
Laura Wormser
VFValerie Fritz
Valerie Fritz
MKMelanie Kappelmann-Fenzl
Melanie Kappelmann-Fenzl
NRNicole Rachinger
Nicole Rachinger
PEPol Escudé
Pol Escudé
PPeter Dietrich
Peter Dietrich
RNA interference (RNAi) therapeutics represent breakthrough discoveries, but their use in cancer remains limited due to hepatocyte-specific targeting. Cancer metastasis is regulated by complex crosstalk between tumor cells and niche-derived factors. However, the molecular mechanisms enabling metastatic seeding and outgrowth in the liver remain incompletely understood, representing a major clinical challenge. We identified neuropeptide Y (NPY) as a promotor of liver metastasis. Hepatocyte-derived NPY attracts metastatic tumor cells to the liver niche. Subsequent microenvironment activation induces TGFβ, promoting a vicious cycle of perimetastatic NPY secretion and liver metastasis. Concomitantly, cancer cells upregulate the NPY-5 receptor (Y5R) which is correlated with liver metastasis. NPY-Y5R crosstalk drives chemotactic migration via cAMP and ERK signaling. Moreover, NPY-Y5R activation dephosphorylates checkpoint kinase 2 to promote clonogenicity and proliferation of cancer cells. Lipid nanoparticles (LNPs) are a promising drug delivery vehicle for siRNAs. LNPs carrying siRNA pools targeting NPY were designed, and preclinical studies provided evidence for efficacy for the treatment of liver metastasis. Our findings transform the limitation of hepatocyte specificity of RNA interference into a therapeutic advantage, introducing a paradigm for the treatment of hepatic metastases.